Large Granular Lymphocytic Leukemia

Indolent clonal expansion of cytotoxic T or NK cells — chronic neutropenia, rheumatoid arthritis association, STAT3/5B mutations, and immunosuppressive therapy

Key Points

• Large granular lymphocytic (LGL) leukemia is a rare, predominantly indolent clonal disorder of cytotoxic T cells (T-LGL, ~85%) or NK cells (NK-LGL, ~15%), characterized by a persistent increase in circulating LGLs (typically >2,000/µL for ≥6 months).
• Chronic neutropenia — often severe (<500/µL) — is the dominant clinical problem, driving recurrent bacterial infections and oral ulcers; anemia (from pure red cell aplasia or hemolytic anemia) and thrombocytopenia occur less commonly.
• STAT3 mutations (most commonly Y640F and D661Y in the SH2 domain) are present in ~40% of T-LGL leukemia and ~30% of NK-LGL; STAT5B mutations occur in a small aggressive subset and predict a poor prognosis.
• A strong association with rheumatoid arthritis (Felty-like syndrome) is present in ~25–30% of T-LGL cases; other autoimmune conditions (hypothyroidism, cytopenias, inflammatory bowel disease) and red cell aplasia occur with increased frequency.
• Treatment is indicated only for symptomatic neutropenia, transfusion-dependent anemia, or severe systemic symptoms; first-line immunosuppression with methotrexate, cyclosporine, or cyclophosphamide achieves response in 40–60% of patients.
• T-LGL leukemia is rarely fatal and often follows a stable chronic course for years; NK-LGL leukemia is more heterogeneous, ranging from indolent to aggressive disease with rapid clinical deterioration.

Classification and Pathogenesis

LGL leukemia encompasses two biologically related but clinically distinct entities: **T-LGL Leukemia:** A clonal expansion of CD3+, CD8+, TCRαβ+ (rarely TCRγδ+) cytotoxic T cells with large granular lymphocyte morphology (abundant pale cytoplasm with azurophilic granules containing cytotoxic proteins: granzyme B, perforin, TIA-1). It is the most common LGL disorder (~85% of cases). Immunophenotype: CD3+, CD8+, CD57+, CD16+/−, CD56−/+, CD28−. Clonal T-cell receptor gene rearrangement is the molecular hallmark. **NK-LGL Leukemia:** A clonal expansion of CD3−, CD56+, CD16+ NK cells. The chronic…

Clinical Features and Associations

T-LGL leukemia predominantly affects adults over 50 years (median age ~60); there is an equal sex distribution. The majority of patients (~60–70%) are asymptomatic at diagnosis, with LGL lymphocytosis identified incidentally on a complete blood count. **Hematologic manifestations:** - *Neutropenia:* The dominant feature in symptomatic patients; absolute neutrophil count (ANC) <500/µL in ~50% of those requiring treatment. Manifestations include recurrent bacterial infections (cellulitis, pneumonia), oral ulcers, and perirectal abscesses - *Anemia:* Moderate anemia occurs in ~50%; pure red…

Diagnosis

Diagnosis of T-LGL leukemia requires integration of clinical, morphological, immunophenotypic, and molecular findings: 1. **Peripheral blood LGL count:** Persistent absolute LGL count >2,000/µL for ≥6 months (some criteria accept >500/µL with clonality confirmation) 2. **Morphology:** Large lymphocytes with pale cytoplasm and azurophilic granules on blood smear 3. **Flow cytometry:** CD3+, CD8+, CD57+, CD16+/−, CD56−/+, CD28−; loss of CD5 or CD7 supports clonality; CD4+ T-LGL is a rare variant 4. **Clonality:** T-cell receptor gene rearrangement by PCR (clonal TCRβ or TCRγ); required for…

Treatment

**Indications for Treatment:** Most T-LGL patients have an indolent course and do not require treatment. Therapy is indicated for: - Symptomatic neutropenia (ANC <500/µL with infections or ANC <1,000/µL recurrently) - Transfusion-dependent anemia or PRCA - Severe or symptomatic thrombocytopenia - Significant splenomegaly causing symptoms - Associated rheumatoid arthritis requiring treatment (T-LGL therapy may improve both) **First-Line Immunosuppressive Therapy:** All three standard agents produce responses in approximately 40–60% of patients; no head-to-head trials exist to determine…

Prognosis and Long-term Management

T-LGL leukemia is generally an indolent, chronic disease with an excellent overall prognosis for most patients. Median OS exceeds 10 years, and many patients survive decades. Disease-related mortality primarily results from infectious complications of neutropenia, particularly in patients with recurrent severe infections who are refractory to immunosuppressive therapy. STAT5B-mutated T-LGL is an important exception — it defines an aggressive variant with rapidly progressive cytopenias, high-grade transformation, and a median OS of less than 1 year. Prompt recognition and aggressive treatment…